MedPath

Collagenase treatment for ocular burns

Recruiting
Conditions
Other specified disorders of cornea,
Registration Number
CTRI/2021/08/035994
Lead Sponsor
Hyderabad Eye Research Foundation
Brief Summary

We propose to investigate the drug Collagenase in a prospective open-label randomized controlled academic clinical trial. In particular, we aim at evaluating the safety and efficacy of topical collagenase for the treatment of adult patients with acute severe unilateral chemical burns. This trial will be single centre, performed at the LV Prasad Eye Institute (LVPEI), in Hyderabad, India.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
30
Inclusion Criteria
  • 1.Patient should be 18 years and above of age.
  • 2.Patient should be able and prepared to complete all required clincial tests and examinations.
  • 3.Patient should be diagnosed with an acute (<14 days after injury) severe (grade II-IV) unilateral chemical burn.
  • 4.Patient should not have any other ocular abnormality in the injured eye.
  • 5.Able to provide informed consent prior to any study related procedures.
Exclusion Criteria

Unwillingness to participate in the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of cases showing complete restoration (epithelialization) of the ocular surface on clinical slit-lamp evaluation using fluorescein staining.28 days
Secondary Outcome Measures
NameTimeMethod
The proportion of patients showing 2-line improvement in BCVA from baseline will be computed along with 95% CIs.The secondary end points will be at 3-months, 6-months and 1-year follow up visit.

Trial Locations

Locations (1)

LV Prasad Eye Institute

🇮🇳

Hyderabad, TELANGANA, India

LV Prasad Eye Institute
🇮🇳Hyderabad, TELANGANA, India
Dr Sayan Basu
Principal investigator
04068102511
sayanbasu@lvpei.org

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.